tetano
Editor, Senior Moderator
J Med Virol
. 2020 Sep 23.
doi: 10.1002/jmv.26537. Online ahead of print.
Convalescent Plasma for the Treatment of Patients with Severe Coronavirus Disease 2019; a Preliminary Report
Ali S Omrani[SUP] 1 2 [/SUP], Ahmed Zaqout[SUP] 1 2 [/SUP], Anas Baiou[SUP] 3 [/SUP], Joanne Daghfal[SUP] 2 [/SUP], Naser Elkum[SUP] 4 [/SUP], Rand A Alattar[SUP] 2 [/SUP], Dana Bakdach[SUP] 5 [/SUP], Hatem Abusriwil[SUP] 6 [/SUP], Abdalrahman M Mostafa[SUP] 6 [/SUP], Bassem Alhariri[SUP] 6 [/SUP], Naseem Ambra[SUP] 6 [/SUP], Mohamed Khatib[SUP] 7 [/SUP], Ali M Eldeeb[SUP] 8 [/SUP], Zeyd Merenkov[SUP] 9 [/SUP], Zeinab Fawzi[SUP] 9 [/SUP], Saloua M Hmissi[SUP] 9 [/SUP], Ali Ait Hssain[SUP] 5 [/SUP], Peter V Coyle[SUP] 10 [/SUP], Hussam Alsoub[SUP] 1 2 [/SUP], Muna A Almaslamani[SUP] 1 2 [/SUP], Abdullatif Alkhal[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: The role of convalescent plasma therapy for patients with Coronavirus Disease 2019 (COVID-19) is unclear.
Methods: We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and those who, in addition, received convalescent plasma (CP Group).
Results: Forty patients were included in each group. The median patient age was 53.5 years [interquartile range (IQR) 42-60.5], and the majority required invasive ventilation (69, 86.2%). Plasma was harvested from donors after a median of 37 days (IQR 31-46) from the first positive SARS-CoV-2 PCR result, and 26 days (IQR 21-32) after documented viral clearance; and was administered after a median of 10 days (IQR 9-10) from onset of symptoms and 2.5 days (IQR 2-4) from admission to ICU. The primary endpoint of improvement in respiratory support status within 28 days was achieved in 26 (65%) in the SC Group, and 31 (77.5%) in the CP Group (P 0.32). All-cause mortality at 28 days (12.5% versus 2.5%, P 0.22), and viral clearance (65% versus 55%, P 0.49) were not significantly different between the two groups. Convalescent plasma was not significantly associated with the primary endpoint (adjusted hazard ratio 0.87; 95% confidence interval 0.51-1.49, P 0.62). Adverse events were balanced between the two study groups.
Conclusion: In severe COVID-19, convalescent plasma therapy was not associated with clinical benefits. Randomized trials are required to confirm our findings. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Coronavirus; SARS-CoV-2; convalescent plasma; passive immunotherapy.
. 2020 Sep 23.
doi: 10.1002/jmv.26537. Online ahead of print.
Convalescent Plasma for the Treatment of Patients with Severe Coronavirus Disease 2019; a Preliminary Report
Ali S Omrani[SUP] 1 2 [/SUP], Ahmed Zaqout[SUP] 1 2 [/SUP], Anas Baiou[SUP] 3 [/SUP], Joanne Daghfal[SUP] 2 [/SUP], Naser Elkum[SUP] 4 [/SUP], Rand A Alattar[SUP] 2 [/SUP], Dana Bakdach[SUP] 5 [/SUP], Hatem Abusriwil[SUP] 6 [/SUP], Abdalrahman M Mostafa[SUP] 6 [/SUP], Bassem Alhariri[SUP] 6 [/SUP], Naseem Ambra[SUP] 6 [/SUP], Mohamed Khatib[SUP] 7 [/SUP], Ali M Eldeeb[SUP] 8 [/SUP], Zeyd Merenkov[SUP] 9 [/SUP], Zeinab Fawzi[SUP] 9 [/SUP], Saloua M Hmissi[SUP] 9 [/SUP], Ali Ait Hssain[SUP] 5 [/SUP], Peter V Coyle[SUP] 10 [/SUP], Hussam Alsoub[SUP] 1 2 [/SUP], Muna A Almaslamani[SUP] 1 2 [/SUP], Abdullatif Alkhal[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32965715
- DOI: 10.1002/jmv.26537
Abstract
Background: The role of convalescent plasma therapy for patients with Coronavirus Disease 2019 (COVID-19) is unclear.
Methods: We retrospectively compared outcomes in a cohort of critical COVID-19 patients who received standard care (SC Group) and those who, in addition, received convalescent plasma (CP Group).
Results: Forty patients were included in each group. The median patient age was 53.5 years [interquartile range (IQR) 42-60.5], and the majority required invasive ventilation (69, 86.2%). Plasma was harvested from donors after a median of 37 days (IQR 31-46) from the first positive SARS-CoV-2 PCR result, and 26 days (IQR 21-32) after documented viral clearance; and was administered after a median of 10 days (IQR 9-10) from onset of symptoms and 2.5 days (IQR 2-4) from admission to ICU. The primary endpoint of improvement in respiratory support status within 28 days was achieved in 26 (65%) in the SC Group, and 31 (77.5%) in the CP Group (P 0.32). All-cause mortality at 28 days (12.5% versus 2.5%, P 0.22), and viral clearance (65% versus 55%, P 0.49) were not significantly different between the two groups. Convalescent plasma was not significantly associated with the primary endpoint (adjusted hazard ratio 0.87; 95% confidence interval 0.51-1.49, P 0.62). Adverse events were balanced between the two study groups.
Conclusion: In severe COVID-19, convalescent plasma therapy was not associated with clinical benefits. Randomized trials are required to confirm our findings. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Coronavirus; SARS-CoV-2; convalescent plasma; passive immunotherapy.